<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133937</url>
  </required_header>
  <id_info>
    <org_study_id>BP29113</org_study_id>
    <nct_id>NCT02133937</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers</brief_title>
  <official_title>A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This single-center, randomized open-label, single-dose, parallel group study will investigate&#xD;
      the relative bioavailability of a high concentration liquid formulation (HCLF) versus the&#xD;
      reference lyophilized formulation (LyoF) of gantenerumab. Healthy volunteers will be&#xD;
      randomized 1:1 to receive single-dose gantenerumab by subcutaneous injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of gantenerumab</measure>
    <time_frame>Up to 13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Approximately 21 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>High Concentration Liquid Formulation (HCLF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lyophilized formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gantenerumab</intervention_name>
    <description>Single subcutaneous injection of a high concentration liquid formulation</description>
    <arm_group_label>High Concentration Liquid Formulation (HCLF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gantenerumab</intervention_name>
    <description>Single subcutaneous injection of a lyophilized formulation</description>
    <arm_group_label>Lyophilized formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects, 40 to 70 years of age inclusive. Healthy status is&#xD;
             defined by absence of evidence any active or chronic disease following a detailed&#xD;
             medical and surgical history, a complete physical examination including vital signs,&#xD;
             12-lead ECG, hematology, blood chemistry, coagulation, serology and urinalysis. Some&#xD;
             medical conditions are allowed that are well controlled by single stable medication&#xD;
&#xD;
          -  A BMI between 18.0 to 30.0 kg/m2 inclusive&#xD;
&#xD;
          -  Use of highly effective contraception until 6 months after study follow-up visit&#xD;
&#xD;
          -  Agree not to donate blood or blood products for transfusion for the duration of the&#xD;
             study and for one year after their dosing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspicion of alcohol or drugs abuse addiction using DSM IV criteria&#xD;
&#xD;
          -  Regular smoker (&gt; 5 cigarettes, &gt; 1 pipeful or &gt; 1 cigar per day), tobacco users and&#xD;
             subjects on nicotine replacement therapy&#xD;
&#xD;
          -  Prior administration of gantenerumab&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 60 days before dosing&#xD;
&#xD;
          -  Donation of blood over 500 mL within three months before dosing&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Any abnormal skin conditions or potentially obscuring tattoos, pigmentation or lesions&#xD;
             in the area intended for subcutaneous injection&#xD;
&#xD;
          -  Any familial history of early onset Alzheimer's disease&#xD;
&#xD;
          -  Claustrophobia, presence of pacemakers, aneurysm clips, artificial heart valves, ear&#xD;
             implants, or foreign metal objects in the eyes, skin or body which would&#xD;
             contraindicate an MRI scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

